| Literature DB >> 34211959 |
Abeer A Sharfalddin1, Abdul-Hamid Emwas2, Mariusz Jaremko3, Mostafa A Hussien1,4.
Abstract
In the search for novel, metal-based drug complexes that may be of value as anticancer agents, five new transition metal complexes of sulfaclozine (SCZ) with Cu(II), Co(II), Ni(II), Zn(II), and Fe(II) were successfully synthesized. The chemical structure of each complex was characterized using elemental analysis (CHN), IR spectroscopy, UV-Vis spectroscopy, thermogravimetric analysis (TGA), and electronic paramagnetic resonance (EPR) spectroscopy. IR spectra indicated that the donor atoms were one sulfonyl oxygen atom and one pyrazine nitrogen atom, which associated with the metal ions to form a stable hexagonal coordination ring. The metal-ligand stability constant (Kf) revealed that Cu(II) and Ni(II) have good coordination stability among the metal compounds. Theoretical studies using DFT/B3LYP were performed to further validate the proposed structures. The obtained results indicated that Cu(II) has a trigonal bipyramidal geometry, whereas Fe(II), Co(II), and Ni(II) have an octahedral structure, while Zn(II) has a tetrahedral arrangement. The bio-activities of the characterized complexes were evaluated using DNA binding titration and molecular docking. The binding constant values for the metal complexes were promising, with a maximum value for the copper metal ion complex, which was 9 × 105 M-1. Molecular docking simulations were also carried out to evaluate the interaction strength and properties of the synthesized metal complexes with both DNA and selected cancer-relevant proteins. These results were supported by in vitro cytotoxicity assays showing that the Cu(II) and Ni(II) complexes display promising antitumor activity against colon and breast cancer cell lines.Entities:
Keywords: DFT; anticancer; electronic paramagnetic resonance analysis; molecular docking; sulfaclozine
Year: 2021 PMID: 34211959 PMCID: PMC8239243 DOI: 10.3389/fchem.2021.644691
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
FIGURE 1Structures of sulfonamide and sulfaclozine.
Analytical and physical data of SCZ and metal complexes.
| Metal complex | M.Wt. | Color | Elemental analysis, % found (calc.) | Λm (Ώcm2 mol-1) | Melting point | |||
|---|---|---|---|---|---|---|---|---|
| C% | N% | S% | M% | |||||
| SCZ | 250.05 | White | 47.99 | 22.39 | 12.31 | - | 1.3 | 130 |
| 48 | 22.40 | 12.30 | ||||||
| [Cu(SCZ)2Cl]Cl | 635 | Yellow ochre | 34.13 | 15.92 | 9.10 | 9.09 | 94 | 170 |
| 34.10 | 15.95 | 9.12 | 9.03 | |||||
| [Co(SCZ)2ClOH2]Cl | 628.39 | Blue | 34.35 | 15.89 | 10.17 | 9.35 | 70 | 205 |
| 34.32 | 15.89 | 10.20 | 8.50 | |||||
| [Ni(SCZ)2Cl2] | 630.15 | Light green | 34.36 | 15.99 | 9.17 | 8.40 | 5.56 | 200 |
| 34.40 | 16.05 | 9.19 | 8.41 | |||||
| [Fe(SCZ)2Cl2] | 627.30 | Dark brown | 34.52 | 16.10 | 9.21 | 8.02 | 1.56 | 158 |
| 34.51 | 15.92 | 9.25 | 8.00 | |||||
| [Zn(SCZ)2]Cl2 | 636.83 | Sandy | 34.04 | 15.60 | 9.09 | 9.26 | 152 | 214 |
| 34.02 | 15.55 | 9.10 | 9.30 | |||||
FIGURE 2EPR spectrum of the Cu–SCZ complex.
Electronic parameters of the metal complexes.
| Compound | Vligand band shift | V3 | V2 | 10Dq | B | β | |
|---|---|---|---|---|---|---|---|
| SCZ | 274(36500) | 313(31500) | - | - | |||
| [Cu(SCZ)2Cl]Cl | 275(36400) | 321(31200) | 810(12346) | 12350 | - | - | |
| [Co(SCZ)2ClOH2]Cl | 278(36000) | 315(31500) | 589(16977) | 685(14600) | 7770 | 708 | 0.730 |
| [Ni(SCZ)2Cl2] | 297(25189) | 405(24700) | 680(14700) | 760(12900) | 5400 | 760 | 0.738 |
| [Fe(SCZ)2Cl2] | 276 | 335(29900) | - | - | - | - | - |
Thermogravimetric data of the five metal complexes.
| Complex | Step | Temp. range | Weight loss % found (calc.) | Assignments | Total mass loss/% found (calc.) | Final solid state residue found (calc.) |
|---|---|---|---|---|---|---|
| [Cu(SCZ)2Cl]Cl.2H2O | 1st | 150–160 | 4.5 (5) | 2H2O | 79.8 (79.9) | CuO 11.3 (11.3) |
| 2nd | 205–240 | 75.3 (74.7) | 2HCl+2SO2+4N2+7C2H4 | |||
| [Co(SCZ)2ClOH2]Cl.2H2O | 1st | 164–172 | 10.1 (10.5) | 2H2O+C2H2+2NH3 | 75.3 (76.1) | CoO+10C 17.4 (18.5) |
| 2nd | 215–246 | 65.2 (65.6) | 2HCl+2SO2+3N2+4C2H2 | |||
| [Zn(SCZ)2]Cl2 | One step | 217–260 | 72.7 (71.9) | 2HCl+2HSO2+4N2+4C2H4 | 72.7 (71.9) | ZnO+7C 20.7 (20.1) |
| [Fe(SCZ)2Cl2].3H2O | 1st | 115–131 | 8.9 (7.8) | 3 H2O | 59.39 (58.9) | Fe2O3+8C 26.49 (27.83) |
| 2nd | 157–177 | 22.5 (23) | 2CN+5C2H2 | |||
| 3rd | 302.33–340 | 13.4 (13.1) | 2N2+SO2 | |||
| 4th | 625–660 | 14.59 (15) | 2N2+SO2 | |||
| [Ni(SCZ)2Cl2].2H2O | 1st | 80–94 | 10.8 (10.5) | 2H2O+2C2H2 | 73.7 (74.4) | NiO+8C 23.2 (23.5) |
| 2nd | 199–234 | 62.9 (63.9) | 2HCl+2SO2+4N2+4C2H2 |
FIGURE 3TG curves of [Cu(SCZ)2Cl]Cl.2H2O, [Co(SCZ)2ClOH2]Cl.2H2O, [Ni(SCZ)2Cl2].2H2O, [Zn(SCZ)2]Cl2.2H2O, and [Fe(SCZ)2Cl2].2H2O complexes.
FIGURE 4The suggested structures of the SCZ metal complexes.
FIGURE 5The optimized geometry with the numbering system of the free SCZ ligand and the five metal complexes.
FIGURE 6HOMO and LUMO plots of the SCZ and the metal complexes using DFT/B3LYP.
FIGURE 7UV absorption spectra of the [Cu(SCZ)2Cl2] complex (A) and the ligand SCZ (B) in a buffer upon the addition of CT-DNA. Plots of [DNA] vs. [DNA]/ϵa-ϵf for the titration of CT-DNA.
FIGURE 83D and 2D views of interactions of 8 with B-DNA.
Energy score (kcal mol-1) calculation for SCZ and its metal complexes toward four protein receptors.
| Protein/complex | SCZ | Cu–SCZ | Co–SCZ | Ni–SCZ | Fe–SCZ | Zn–SCZ | |
|---|---|---|---|---|---|---|---|
| Colon cancer protein | 2X7F | –5.67657 | –6.67613 | –6.39108 | –5.68732 | –6.39108 | –6.36569 |
| 4F9M | –6.55138 | –7.24939 | –6.71789 | –6.88243 | –6.80609 | –7.2411 | |
| Breast cancer protein | 3ERT | –6.02021 | –6.5352 | –6.18126 | –6.0157 | –6.24734 | –6.01604 |
| 1H7K | –5.49007 | –7.73247 | –6.22617 | –6.80484 | –6.55553 | –7.10101 | |
2D and 3D molecular docking mode and interaction between SCZ and the Cu(II) complex with the colon protein receptor (2X7F) and the breast protein receptor (3ERT).
|
|
Cytotoxic activity of SCZ and its metal complexes against human tumor cells and SD values.
| Compound | In vitro cytotoxicity IC50 (µg/ml) | |||
|---|---|---|---|---|
| Breast cell line (MCF-7) | SD | Colon cell line (CaCo-2) | SD | |
| SCZ ligand | 215.24 | ±0.67 | 97.6 | ±0.45 |
| [Cu(SCZ)2Cl]Cl | 86.2 | ±0.64 | 23.84 | ±0.33 |
| [Zn(SCZ)2]Cl2 | 111.91 | ±0.36 | 198.44 | ±0.25 |
| [Ni(SCZ)2Cl2] | 45.62 | ±0.28 | 106.87 | ±0.34 |
| [Co(SCZ)2ClOH2]Cl | 54.23 | ±0.52 | 190.1 | ±0.30 |
| [Fe(SCZ)2Cl2] | 284.25 | ±0.31 | 362.9 | ±0.41 |
IC50 (mg/ml): 1–10 (very strong), 11–20 (strong), 21–50 (moderate), 51–100 (weak), and above 100 (non-cytotoxic).